Parametrica Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Parametrica Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,814	Closed	-$1.18M	–	382
2016 Q4	$1.18M	Buy	+10,814	New	+$1.29M	1.16%	8
2016 Q1	–	Sell	-1,495	Closed	-$223K	–	131
2015 Q4	$223K	Buy	+1,495	New	+$253K	1.47%	35
2014 Q2	–	Sell	-1,058	Closed	-$349K	–	89
2014 Q1	$349K	Buy	+1,058	New	+$357K	2.96%	5

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parametrica Management's ICPT Position: Q1 2017 in Review

Parametrica Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2017, closing a stake of 10,814 shares — an estimated $1.18M sold.

Parametrica Management first reported a position in ICPT in Q1 2014 and held it in 3 quarters. The position peaked at $1.18M in Q4 2016. 150 funds tracked by Wall St. Rank hold ICPT as of Q1 2017.

Parametrica Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Parametrica Management sold 10,814 Intercept Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.18M.
Parametrica Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
Parametrica Management's Intercept Pharmaceuticals, Inc. position peaked at $1.18M in Q4 2016.
150 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2017.

Based on Parametrica Management's 13F filing for Q1 2017, filed 13 Apr 2017.